-

Allurion Technologies Names Digital Product Innovator Jeff Feldgoise as Head of Digital Product

Company taps seasoned, entrepreneurial executive as it expands its digital offering

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, a pioneering leader in the development of innovative, scalable and trusted weight loss experiences, today announced the addition of Jeff Feldgoise as Head of Digital Product. Feldgoise will oversee and expand the company’s digital engineering, product, and design teams with a focus on building the next generation of best-in-class digital weight loss experiences.

“For almost two decades, Jeff has created frictionless digital experiences that delight consumers and are built to scale,” said Shantanu Gaur, M.D., Allurion’s co-founder and Chief Executive Officer. “Under Jeff’s leadership, we will introduce digital features and capabilities into our existing platform that are clinically proven, and we will continue in our pursuit of building a new category of weight loss experiences that integrate medical, nutritional, and digital approaches.”

Prior to joining Allurion, Feldgoise held leadership roles with leading healthcare technology and financial technology companies. Most recently, he served as Vice President of Product and Marketplace at Slingshot Health where he led a team that developed an online service matching patients and providers to make care delivery more accessible and affordable. Previously, Jeff held leadership roles at a number of companies, including Fidelity Investments, where he developed and launched best-in-class consumer investment experiences, from the original Fidelity.com to their #1-rated automated robo-advisor, Fidelity Go, that scaled rapidly to billions of dollars of investments.

“I am delighted to join the world-class team at Allurion as they continue scaling a truly unique weight loss experience around the globe,” said Jeff Feldgoise, Head of Digital Product, Allurion Technologies. “I am excited to build a ground-breaking digital consumer experience that people will love to use, leveraging clinically proven strategies for weight loss and behavior change, and helping millions of people everywhere achieve a healthy weight.”

About Allurion Technologies

Allurion Technologies is dedicated to helping people realize their full potential with innovative, scalable and trusted experiences. The company's flagship product, the Elipse Program, is a 360-degree weight loss experience featuring the Elipse Balloon, the world’s first and only swallowable, procedureless gastric balloon for weight loss. Learn more about the Elipse Balloon and Allurion online at www.allurion.com, on Facebook at www.fb.com/allurion or on Twitter @alluriontech.

Contacts

Paul Kidwell
(617) 680-1088

Allurion Technologies


Release Summary
Allurion Technologies announces digital acceleration and new hire Jeff Feldgoise as Head of Digital Product
Release Versions

Contacts

Paul Kidwell
(617) 680-1088

More News From Allurion Technologies

Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a partnership with Bionut, a leader in obesity care in Argentina, and Farmastar, a local pharmacy partner with access to the official supplier of Mounjaro (tirzepatide) in Argentina, to provide patients with access to discounted Mounjaro to be used in combination with the Allurion Smart Capsule. “The obesity epidemic is growing, and patients are in need of mo...

Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced preliminary, unaudited results for the fourth quarter and full year 2025. Management expects preliminary, unaudited results for the period as follows: Fourth quarter revenue of $3.3 million to $3.7 million, a 22% to 37% increase quarter-over-quarter, and full-year revenue of approximately $15 million Substantial improvement in operating expenses and operating...

Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced initial results on the combination of the Allurion Program with low-dose tirzepatide therapy to optimize muscle mass and GLP-1 adherence. 76 patients treated with the Allurion Smart Capsule were started on low-dose tirzepatide after completing their first 45 days of balloon therapy. The starting dose of tirzepatide was 2.5mg and...
Back to Newsroom